-
Mashup Score: 14Fusion genes in pancreatic tumors - 2 month(s) ago
Gene fusions and rearrangements play a crucial role in tumor biology. They are rare events typically detected in KRAS wild-type (WT) pancreatic tumors…
Source: www.sciencedirect.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 34
This systematic review and meta-analysis compares survival, response, and toxic effects among patients with pancreatic cancer treated with fluorouracil, leucovorin, liposomal irinotecan and oxaliplatin (NALIFIROX); fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX); or gemcitabine…
Source: jamanetwork.comCategories: General Medicine News, Hem/OncsTweet-
RT @ArndtVogel: NALIRIFOX, FOLFIRINOX & GEM-NAP as 1st line CTx for #PDAC @JAMANetworkOpen https://t.co/9wxcPxzhrx 🔎Systematic Review & Me…
-
-
Mashup Score: 34
This systematic review and meta-analysis compares survival, response, and toxic effects among patients with pancreatic cancer treated with fluorouracil, leucovorin, liposomal irinotecan and oxaliplatin (NALIFIROX); fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX); or gemcitabine…
Source: jamanetwork.comCategories: General Medicine News, Hem/OncsTweet-
RT @ArndtVogel: NALIRIFOX, FOLFIRINOX & GEM-NAP as 1st line CTx for #PDAC @JAMANetworkOpen https://t.co/9wxcPxzhrx 🔎Systematic Review & Me…
-
-
Mashup Score: 3
The AMPLIFY-7- trial is evaluating the investigational therapeutic cancer vaccine ELI-002 7P in patients with solid tumors that harbor KRAS or NRAS mutations.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet-
The first patient with KRASm #PDAC has been dosed with ELI-002 7P in AMPLIFY-7P. "By initiating this study, we seek to determine if ELI-002 7P could be a treatment option for this patient population," explained Christopher Haqq, MD, PhD, of @ElicioTx. https://t.co/7icdwXLe26 https://t.co/R35hJaEGqh
-
-
Mashup Score: 2New Uses for Existing Treatments: The Practice of Drug Repurposing - 7 month(s) ago
The practice of studying existing drugs for novel uses is supported by the emergence of artificial intelligence.
Source: www.cedars-sinai.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
Thx @CedarsSinai Discoveries magazine for covering one of my 1st #IITs in #PDAC, repurposing a drug based on findings in the lab. Grateful for my @CSCancerCenter partners @DrHendifar @DrArsenOsipov for putting their patients on this study @CedarsSinaiMed https://t.co/KPEuBJsDsr
-
-
Mashup Score: 10Coordinated single-cell tumor microenvironment dynamics reinforce pancreatic cancer subtype - 8 month(s) ago
Nature Communications – Multiple studies have characterised the tumour microenvironment (TME) of pancreatic ductal adenocarcinoma (PDAC) using single-cell RNA-seq. Here, the authors integrate the…
Source: www.nature.comCategories: General Medicine News, Latest HeadlinesTweet-
Integration of #PancreaticCancer #scRNAseq studies provides a cohesive analysis of the tumour #microenvironment #PDAC #CancerResearch @NatResCancer https://t.co/TQz8AlX9ei
-
-
Mashup Score: 4Smoking Impairs the Effect of Neoadjuvant FOLFIRINOX on Postresection Survival in Pancreatic Cancer - 8 month(s) ago
Smoking plays an important role in carcinogenesis, including pancreatic ductal adenocarcinoma (PDAC). However, little is known about the association b…
Source: www.sciencedirect.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
RT @ArndtVogel: Smoking Impairs the Effect of Neoadjuvant FOLFIRINOX on Postresection OS in #PDAC @OncologyAdvance https://t.co/bCniEKVPLH…
-
-
Mashup Score: 2A Call for Caution in Overinterpreting Exceptional Outcomes ... : Annals of Surgery - 9 month(s) ago
An abstract is unavailable.
Source: journals.lww.comCategories: Latest Headlines, Oncologists1Tweet-
Would direct folks to our commentary on this 👉🏽https://t.co/X6TOiHiSbZ. Applaud surgeons (& patients) who take this on. All high volume #PDAC surgeons/🏥, including ours, do art rsxn SELECTIVELY. But such series should NOT be🟢💡for inexperienced centers to offer indiscriminately https://t.co/AjtChGxKuo
-
-
Mashup Score: 0
The phase 2b VIRAGE study evaluating the combination of VCN-01 with standard-of-care chemotherapy in patients with pancreatic cancer remains on track to be fully-enrolled in the first quarter of 2024.
Source: www.targetedonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The phase 2b VIRAGE study of VCN-01 with gemcitabine/nab-paclitaxel as a first-line treatment for patients with metastatic #PDAC has now begun dosing patients in the United States. #pancsm https://t.co/U7NZibmYSR
-
-
Mashup Score: 3Wolters Kluwer Health - 10 month(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…
Source: lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Antibiotics may improve survival outcomes for pancreatic ductal adenocarcinoma (PDAC) patients receiving gemcitabine-based chemotherapy. Antibiotics targeting Gammaproteobacteria showed promising results. #PDAC #PancreaticCancer https://t.co/aJ8dKE2WTa https://t.co/XWBmnx1VCO
-
RT @ArndtVogel: Fusion genes in pancreatic tumors @trendscancer https://t.co/20VGt3sRnQ 👉in 1.4% of #PDAC cases (98% KRAS WT, > acinar neop…